Roche

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

One in four diabetics has undiagnosed heart failure; study

A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Roche's AI-powered digital pathology open environment in action

Roche accelerates AI adoption with NVIDIA deal

Roche has ramped up its investment in NVIDIA's AI chips, launching a hybrid-cloud AI factory that it believes is the largest in the pharma industry.

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

Roche places a $1bn bet on C4T degrader-antibody conjugates

Alzheimer's biotech Korsana to go public via reverse merger

One in four diabetics has undiagnosed heart failure; study

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Roche accelerates AI adoption with NVIDIA deal

Roche's oral SERD flunks phase 3 breast cancer test

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks